Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Surg Oncol ; 22(4): 1207-13, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25316487

ABSTRACT

BACKGROUND: Surgery is still the only curative treatment for medullary thyroid cancer (MTC). We evaluated clinical outcome in patients with locoregional MTC with regard to adequacy of treatment following ATA guidelines and number of sessions to first intended curative surgery in different hospitals. METHODS: We reviewed all records of MTC patients (n = 184) treated between 1980 and 2010 in two tertiary referral centers in the Netherlands. Symptomatic MTC (palpable tumor or suspicious lymphadenopathy) patients without distant metastasis were included (n = 86). Patients were compared with regard to adequacy of surgery according to ATA recommendations, tumor characteristics, number of local cancer reoperations, biochemical cure, clinical disease-free survival (DFS), overall survival (OS), and complications. RESULTS: Adherence to ATA guidelines resulted in fewer cancer-related reoperations (0.24 vs. 0.60; P = 0.027) and more biochemical cure (40.9 vs. 20 %; P = 0.038). Surgery according to ATA-guidelines on patients treated in referral centers was significantly more often adequate (59.2 vs. 26.7 %; P = 0.026). Tumor size and LN+ were the most important predictors for clinical recurrence [relative risk (RR) 4.1 (size > 40 mm) 4.1 (LN+) and death (RR 4.2 (size > 40 mm) 8.1 (LN+)]. CONCLUSIONS: ATA-compliant surgery resulted in fewer local reoperations and more biochemical cure. Patients in referral centers more often underwent adequate surgery according to ATA-guidelines. Size and LN+ were the most important predictors for DFS and OS.


Subject(s)
Carcinoma, Medullary/pathology , Carcinoma, Medullary/surgery , Practice Guidelines as Topic , Reoperation/statistics & numerical data , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Thyroidectomy/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Follow-Up Studies , Humans , Lymph Nodes/pathology , Lymph Nodes/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Staging , Postoperative Complications , Prognosis , Retrospective Studies , Tertiary Care Centers , Young Adult
2.
Clin Endocrinol (Oxf) ; 72(4): 534-42, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19563448

ABSTRACT

CONTEXT: In the management of patients with medullary thyroid carcinoma (MTC), calcitonin doubling time (dt) has gained interest as an independent predictor of recurrence and survival. OBJECTIVE: To perform a structured meta-analysis of the diagnostic value of calcitonin dt, carcinoembryonic antigen (CEA) dt and the combination and to define dt strata with the highest predictive power. Design The study was a meta-analysis using individual data. METHODS: Ten studies containing data on the post-operative kinetics of tumour marker(s) and (recurrence free) survival were included. RESULTS: Calcitonin- and CEA-dt are significant indicators for survival (hazard ratios (HR) 21.52 respectively infinite for dt 0-1 year compared to dt >1 year) and recurrence (HR 5.33 respectively 6.80 for dt 0-1 year compared to dt >1 year). The highest predictive power was found for the dt classification 0-1 year vs. >1 year. CEA dt has a higher predictive value than calcitonin dt in the subgroup of patients for which both parameters were available. CONCLUSION: The dts of both calcitonin and CEA are strong prognostic indicators for MTC recurrence and death. CEA dt has a higher predictive value than calcitonin dt and therefore measuring both tumour markers is essential for proper risk stratification.


Subject(s)
Calcitonin/metabolism , Carcinoembryonic Antigen/metabolism , Carcinoma, Medullary/diagnosis , Thyroid Neoplasms/diagnosis , Adolescent , Adult , Aged , Carcinoma, Medullary/pathology , Carcinoma, Medullary/surgery , Disease-Free Survival , Female , Humans , Male , Middle Aged , Postoperative Period , Predictive Value of Tests , Prognosis , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...